The Effect of Simvastatin on Desensitization of Panel-Positive Kidney Transplant Candidates

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Study Completion Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with panel reactive antibodies have many difficulties to find a crossmatch-negative kidney for transplantation and are at the risk of post transplantation rejection more than other transplanted patients. We evaluated the effect of simvastatin on PRA and post transplant outcome of these sensitized patients. We also performed a descriptive study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Novel Desensitization Kidney Transplantation

NCT05345717

Kidney Transplantation End Stage Kidney Disease (ESRD)

COMPLETED PHASE1/PHASE2

Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation

NCT00352547

Renal Transplant

COMPLETED

Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients

NCT00306397

Kidney Transplantation

COMPLETED PHASE4

Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

NCT03507348

End-stage Renal Disease Kidney Transplantation Hla-incompatible Kidney Transplant Candidates

TERMINATED NA

Comparisone of Iminoral Versus Neoral in Prevention of Acute Rejection in Renal Transplantation

NCT00656695

End Stage Renal Disease Renal Transplantation

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The presence of panel reactive antibodies (PRAs) in the sera of renal transplant candidates is associated with hyperacute or delayed humoral immune responses against the graft after transplantation .

In addition, these sensitized patients wait for a long time to find a cross-match negative kidney for renal transplantation . As a result, some modalities have been used for desensitization including plasmapheresis and intravenous immunoglobulin (IVIG) in combination with immunosuppressive drugs .

However, recently, the use of statins such as simvastatin, pravastatin and etc. has been proposed to be safer and more effective for desensitization .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

patients who will take simvastatin 20 mg daily

Group Type EXPERIMENTAL

simvastatin

Intervention Type DRUG

20 mg simvastatin daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

simvastatin

20 mg simvastatin daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients with ESRD on hemodialysis or peritoneal dialysis
2. On the waiting list for renal transplant
3. PRA more than 25%

Exclusion Criteria

1. Pregnant women
2. Patients who need ongoing blood products
3. Patients taking other therapies to decrease PRA
4. Patients listed for multi-organ transplant other than kidney
5. Patients with liver failure

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No